
Erik F Lamberth MD
Sr Medical Director, Vaccines Clinical Research, Pfizer
Join to view full profile
500 Arcola RdCollegeville, PA 19426
Phone+1 215-920-8509
Dr. Lamberth is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Experience at Pfizer as a Global Program Lead, Clinical Lead or Clinician for pediatric and adult clinical trials spanning Phases 1-3 in the Pneumococcal, Covid-19, C. difficile, Lyme and Meningococcal programs. These efforts have contributed to the licensure of several vaccines.
Associate Scholar at the Center for Clinical Epidemiology and Biostatistics at the Perelman School of Medicine at the University of Pennsylvania.
Prior to joining Pfizer, over 18 years of experience as a site investigator for numerous currently licensed vaccines and a practicing physician who discussed vaccines with parents and patients on a daily basis. Over 16 years as an IRB chair, overseeing approximately 35 concurrent clinical trials in oncology, cardiology, and vaccines.
Education & Training
Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 1995 - 1998
Lewis Katz School of Medicine at Temple UniversityClass of 1995
Certifications & Licensure
PA State Medical License 1997 - 2026
American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- National Medal of Technology and Innovation, Company Award for the Pfizer Covid-19 Vaccine, team member United States Government/ President of the United States, 2024
Publications & Presentations
PubMed
- 2 citationsSafety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.Federico Martinon-Torres, Erik Lamberth, Silvina Natalini Martinez, Ignacio Salamanca de la Cueva, Lefteris Zolotas
Human Vaccines & Immunotherapeutics. 2025-12-01 - 17 citationsCLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adu...Curtis J Donskey, Erik R Dubberke, Nicola P Klein, Elizabeth G Liles, Katarzyna Szymkowiak
Clinical Infectious Diseases. 2024-12-17 - 10 citationsA phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.Shane Christensen, Salim Bouguermouh, Kumar Ilangovan, Michael W Pride, Chris Webber
Vaccine. 2023-12-07
Press Mentions
Another Injectable Toxoid Vaccine Flops for C. DiffAugust 28th, 2024
Committees
- Chair, Grand View Hospital IRB 2001 - 2016
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:








